Genvor Restores Trading Status and Expands Global Collaborative Research Network

Rhea-AI Summary

Genvor (OTCID: GNVR) regained active OTCQB trading status on October 9, 2025, positioning the company to accelerate capital formation as it scales field trials and commercialization efforts.

The company said it now operates a newly opened laboratory in Woodland, California to support R&D for foliar and peptide-based formulations, and it is advancing four international research collaborations across Europe, Brazil, and the United States focused on peptide-based seed traits and foliar applications.

Management highlighted that these developments support product validation, global field trials, and expanded scientific capabilities for sustainable agriculture.

Positive

• OTCQB trading status restored on Oct 9, 2025
• Opened and staffed Woodland, California R&D laboratory
• Advancing 4 R&D collaborations across Europe, Brazil, and the United States
• Progressing multiple peptide applications including seed traits and foliar formulations

Negative

• No financial terms, fundraising size, or timetable for capital formation disclosed
• No quantified commercialization timeline or revenue guidance provided

Woodland, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCID: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced that it has regained active OTCQB trading status on OTC Markets, positioning the company to accelerate capital formation as it scales field trials across multiple continents and crop applications. The reinstatement reflects the company’s ongoing commitment to compliance, transparency, and long-term growth as it advances four active research and development collaborations spanning three continents.

“Restoring OTCID trading status marks an important milestone in Genvor’s progression,” said CEO, Chad Pawlak. “With our new California laboratory operational and four international collaborations advancing through field trials, we are building meaningful global collaborations and expanding our scientific capabilities to deliver tangible innovation in sustainable agriculture.”

Genvor is actively collaborating with four research and development projects in Europe, Brazil, and the United States. These collaborations focus on advancing peptide-based formulations and sustainable crop protection to enhance resilience and performance under diverse field conditions. The company is trialing multiple applications of its peptides including seed traits and various foliar formulations. 

The company recently opened and staffed a laboratory in Woodland, California, which supports R&D for foliar and peptide-based formulations. The lab complements Genvor’s ongoing international field programs and development efforts.

Genvor is building momentum through new and ongoing collaborations that support product validation and future commercialization. The company invites forward-thinking partners and investors to join its mission of developing science-based, sustainable technologies that improve agricultural performance and environmental outcomes.

About Genvor
Genvor (OTCQB: GNVR) is pioneering the future of sustainable agriculture through its proprietary AI-accelerated peptide design platform that transforms single discoveries into multi-crop protection and optimization opportunities across diverse agricultural environments. The company’s proprietary BioCypher Algorithm combines computational biology, machine learning, and regulatory benchmarks to create peptides that optimize agricultural outcomes with biological safety. With 2 issued U.S. patents covering antimicrobial and nutrient-enhancing peptides and 24 proprietary peptides in active development, Genvor offers ready-to-deploy licensing opportunities that integrate with existing production infrastructure and regulatory frameworks. For more information, visit www.genvor.com.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed or implied. Genvor undertakes no obligation to update forward-looking statements except as required by applicable law.

Contacts:
 
Investor Relations
Genvor Incorporated 
Marketing@genvor.com
www.genvor.com

Media
Carly Scaduto
carly@carlyscadutoconsulting.com 

FAQ

What does Genvor's restored OTCQB status mean for GNVR shareholders?

Restoring OTCQB status on Oct 9, 2025 resumes active trading for GNVR and may help the company pursue capital formation and investor access.

Where is Genvor's new laboratory located and what does it support for GNVR?

Genvor opened a laboratory in Woodland, California to support R&D for foliar and peptide-based formulations tied to GNVR's field programs.

How many and where are Genvor's international collaborations for GNVR?

Genvor is advancing four collaborations with active field trials across Europe, Brazil, and the United States.

What peptide applications is Genvor trialing under GNVR?

The company is trialing multiple peptide uses, including seed traits and various foliar formulations.

Does Genvor disclose funding amounts or a commercialization timeline for GNVR?

No—there were no funding amounts or specific commercialization timelines disclosed in the announcement.